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Background:  People  with  substance  use  disorder  (SUD)  are  at signiﬁcantly  greater  risk  of  suicide  compared
with the  general  population.  In  recent  years  the number  of  suicides  resulting  from  drug  poisoning  in
England  and  Wales  has increased.  We  sought  to identify  and  evaluate  the  effect  of interventions  to  prevent
suicide  or  reduce  self-harm  among  people  with  SUD.
Methods:  We  conducted  a systematic  review  of randomised  controlled  trials  (RCTs)  of  interventions  for
people with  SUD  that included  suicide  or  self-harm-related  primary  outcomes.  We  searched  Cochrane
Central  Register  of  Controlled  Trials  (CENTRAL),  PsycINFO,  PubMed,  Embase  and  Web of  Science  from
inception  until  13th  January  2019.  Studies  were  assessed  for bias  using  the  Cochrane  Risk  of Bias  2  tool.
A  random  effects  meta-analysis  of  standardised  mean  differences  (SMD)  was  conducted.
Results:  We  identiﬁed  six RCTs  from  four countries  (Australia,  Iran,  the  United  States  of America  and  the
United  Kingdom)  comprising  468  participants  in  total. All  but  one  study  investigated  psychosocial  inter-
ventions.  On average  across  studies  there  was  weak  evidence  of a small  positive  effect  of  interventions
on  suicide  or  self-harm  outcomes  (d  = −0.20,  95% CI  = −0.39–0.00).
Limitations: Studies  were  heterogeneous  in  terms  of population,  intervention,  controls  and  outcome.
There  were  some  concerns  regarding  bias  for all  trials.  All trials  were  liable  to type  II error.
Conclusions:  Evidence  is currently  lacking  regarding  the effectiveness  of interventions  to  prevent  suicide
and  reduce  self-harm  amongst  people  with  SUD.
©  2019  Published  by Elsevier  Inc.  This  is an  open  access  article  under the  CC  BY-NC-ND  license. Introduction
Globally, people with substance use disorder (SUD) are at signif-
cantly greater risk of suicide compared with the general population
1]. SUD is also widely recognised as an important modiﬁable risk
actor for suicide [2], with 45% and 33% of those who  died by sui-
ide in England whilst in contact with services, having a history
f alcohol or other drug misuse respectively [3]. Furthermore, in
ver half of National Health Service suicide-related compensation
laims, the deceased had a history of substance misuse [4].
∗ Corresponding author at: Oakﬁeld House, Oakﬁeld Grove, Bristol, BS8 2BN,
nited Kingdom.
E-mail address: prianka.padmanathan@bristol.ac.uk (P. Padmanathan).
ttps://doi.org/10.1016/j.comppsych.2019.152135
010-440X/© 2019 Published by Elsevier Inc. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/4.0/).
There are numerous biopsychosocial mechanisms, which may
contribute to the increased risk of suicide amongst people with
SUD. These include: 1) SUD leading to unemployment, social isola-
tion and marginalisation; 2) substance use inﬂuencing cognition
and behaviour, which may  result in disinhibition and impulsiv-
ity; and 3) pain, distress and psychiatric conditions increasing the
likelihood of both SUD and suicide [5–7]. In light of these spe-
ciﬁc mechanisms, it cannot be assumed that interventions targeting
suicide and self-harm reduction in the general population can be
applied to people with SUD; more speciﬁc strategies may  need to
be utilised in this particular population.In recent years there has been a large increase in the incidence of
drug-related deaths in England and Wales; the rate peaked in 2016
at the highest level since records began [8]. Although the major-
ity of these deaths are considered accidental poisonings, suicidal
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ntent can be extremely difﬁcult to determine [5], and an increase
n the number of suicides resulting from drug poisoning has been
dentiﬁed as a contributory factor [9].
Current research and guidelines on co-existing severe mental
llness and substance misuse provide minimal evidence regarding
he management of suicide risk or self-harm in this population
10,11]. Furthermore, substance misuse is often an exclusion cri-
erion when researching interventions. In two Cochrane reviews
f interventions for self-harm, over a quarter of studies speciﬁed a
ype of substance misuse in their exclusion criteria [12,13]. In light
f the absence of clear guidelines in this area, we sought to iden-
ify and evaluate the effect of interventions to prevent suicide or
educe self-harm speciﬁcally for people with SUD.
. Method
This systematic review was conducted in accordance with the
ochrane Collaboration framework guidelines, [14] and reporting
onforms to the Preferred Reporting Items for Systematic Reviews
nd Meta-Analyses (PRISMA Statement) [15]. The review protocol
s accessible on PROSPERO CRD42017076236.
The population of interest in this review was any person misus-
ng at least one substance, which included alcohol but excluded
obacco. The intervention and comparison groups were unspec-
ﬁed. The outcomes of interest were suicide, suicidal ideation,
uicide attempts or non-suicidal self-harm (or a combination of
he latter two, commonly referred to as self-harm).
.1. Search strategy
The following databases were searched for publications, with-
ut language restriction, from the inception of each database to
3th January 2019: Cochrane Central Register of Controlled Trials
egister, PsycINFO, PubMed, Embase and Web  of Science. Search
erms broadly included: (substance (including alcohol)) AND (mis-
se) AND (suicide OR self-harm) AND (randomised controlled trial).
he full search strategies are included in Supplementary File 1. Ref-
rence lists of all included studies and key systematic reviews of
elated interventions were screened to identify additional studies
10,12,13,16–20].
.2. Eligibility criteria
Studies were included if they: 1) were individualised or cluster
andomised controlled trials (RCTs); 2) included only participants
ho misused substances including alcohol but excluding tobacco;
) investigated suicide, suicidal ideation, suicide attempts or non-
uicidal self-harm as a primary outcome. Studies were excluded if
he suicide- or self-harm-related outcomes were reported as sec-
ndary or supplementary outcomes. This distinction diverges from
he pre-speciﬁed protocol, due to the difﬁculty in identifying all
tudies including relevant secondary outcomes and consequently
he risk of publication bias. Reviews were excluded, but were used
s a secondary source for relevant papers. No restrictions were
pplied based on participants’ age or comorbidities.
.3. Data extraction and quality assessment
Two authors (out of P.P., K.H., and V.C.) independently screened
itles and abstracts, reviewed full texts of all potentially relevant
tudies, extracted data using a standardised extraction form (Sup-
lementary File 2) and assessed included studies for bias using the
ochrane Risk of Bias 2 Assessment Tool (Supplementary File 3)
21]. The review aimed to assess the effect of introducing an inter-
ention within a health system; therefore only intention-to-treat
nalyses were of interest. Authors were contacted to request studyrehensive Psychiatry 96 (2020) 152135
protocols to enhance the accuracy of the assessments. The overall
risk of bias (ROB) for each study was classiﬁed as ‘low’ if all domains
were judged to be low risk of bias, ‘some risk of bias’ if some con-
cerns regarding bias were identiﬁed in one to four domains but no
domains were considered to be high risk of bias, and ‘high risk of
bias’ if one or more domains was  judged to be at high risk of bias or
there were some concerns regarding risk of bias for all ﬁve domains.
Disagreements were resolved by discussion.
2.4. Data analysis
To maximise comparability of results, we  present only follow-up
data at six months (or as close to six months as possible).
We present tables of study-speciﬁc standardised mean differ-
ences (SMDs) for continuous outcomes and odds ratios (ORs) for
binary outcomes, each with 95% conﬁdence intervals (CIs). In order
to pool across outcome types in a meta-analysis, we approximated
SMDs and standard errors of SMDs from ORs using standard for-
mulae [22].
As our eligibility criteria were broad, we anticipated hetero-
geneity in all aspects of the population, intervention, comparison
and outcome (PICO) framework. We therefore performed a ran-
dom effects meta-analysis as our primary analysis, with a ﬁxed
effect model as a sensitivity analysis. We  tested for statistical het-
erogeneity using the Cochran Q test and estimated the proportion
of variability in effect estimates due to heterogeneity using the
I2 statistic [23]. We  have also presented a 95% prediction interval
in addition to pooled estimates; this represents uncertainty about
the likely true intervention effect in a future study, allowing for
heterogeneity in the population of studies to date [24].
For one study, where there was  more than one intervention
group consisting of different doses of medication, the largest and
smallest doses were compared due to ambiguity with regards to
classiﬁcation of the middle dose as an intervention or control [25].
Where a single study included two  relevant primary outcome mea-
sures, these were averaged to form a composite SMD [22,26]. The
correlation (r) between outcomes was  unknown, and was assumed
to be 0.5, as all outcomes were expected to be positively correlated.
The possibility of publication bias or other form of small study
effects was assessed by inspection of a funnel plot (Supplementary
File 4). Analyses were conducted using Stata [27].
3. Results
3.1. Search results
Our search (Supplementary File 1) identiﬁed 6862 references,
of which 2214 were duplicates. After screening titles and abstracts,
4577 articles were excluded. Of 71 full-texts assessed for eligibil-
ity, seven were included, which described six RCTs [25,26,28–32])
(Fig. 1).
3.2. Study characteristics
Study characteristics are summarised in Table 1. All studies were
individually randomised. Three of the included RCTs were based in
the USA [29–32]. The remaining trials were based in Australia [26],
the UK [28] and Iran [25]. With regards to the population included,
three trials included people who misused alcohol only [28,30–32],
two included people with alcohol and drug misuse [26,29], and one
included only people with severe opioid use disorder [25]. Four
studies restricted the population to those who reported suicidal
ideation [26,29,32], had attempted suicide [26,29], or presented to
hospital with self-harm [28]. Additional inclusion criteria in three
trials were major depressive disorder [25], borderline personality
disorder [30,31] and high emotional dysregulation [32]. All studies
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Table 1
Summary of included studies (CBT: Cognitive behavioural therapy; DBT: dialectical behavioural therapy; DDT: dynamic deconstructive psychotherapy; FRAMES: Feedback about the adverse effects of excessive alcohol consumption,
an  emphasis on Responsibility for change lying with the individual, provision of Advice about reducing alcohol consumption, a Menu of options for further intervention if this is required, an Empathic stance towards the patient,
and  the enhancement of Self-efﬁcacy).
Study Country Participants Substance misuse Mental health
comorbidity
Age/ sex if
restricted
Setting of
recruitment and
intervention
Intervention Comparison group Outcome Risk of bias
Ahmadi et al. [25] Iran N = 51 Severe opioid use
disorder
Major depressive
disorder
Male Recruited from and
delivered on
inpatient
psychiatric ward
Single, sublingual
dose of
buprenorphine
(96 mg)
Single, sublingual
dose of
buprenorphine
(32 mg)
Beck Scale for
suicide ideation
Some concerns
Crawford et al. [28] UK N = 103 Alcohol misuse Nil speciﬁed >18 years Recruited from
emergency
department
‘FRAMES’ approach
Single 1:1 session
& leaﬂet
Leaﬂet Re-attendance at
emergency
department with
self-harm within 6
months
Some concerns
Esposito-Smythers
et  al. [29]
USA N = 40 Alcohol/ cannabis
use disorder
Nil speciﬁed 13-17 years Recruited from
inpatient units
Outpatient
intervention
CBT
Separate 1:1
sessions for
adolescents and
parents with
reducing frequency
from twice weekly
to monthly over 12
months
Enhanced
treatment as usual
Suicidal ideation
over previous
month (Suicidal
Ideation
Questionnaire-
Senior
Version)
High
Gregory et al.
[30,31]
USA N = 30 Alcohol misuse/
dependence
Borderline
personality
disorder
18-45 years Recruited through
range of clinical
settings including
emergency
department and
hospital settings
Outpatient
intervention
DDT
Weekly 1:1
sessions +/- group
therapy over 12-18
months
Optimised
community care
Self-harm (adapted
3 month version of
the Lifetime
Parasuicide Count)
High
Morley  et al. [26] Australia N = 185 Alcohol/ drug
misuse
Nil speciﬁed 18-65 years Recruited from
emergency dept. or
outpatient drug
and alcohol
services
Outpatient
intervention
CBT
8 × 1:1 sessions
with homework
and 1x focus group
session 3 months
later
Treatment as usual a) Presence of
suicide ideation
(weekly)
b) Beck Scale for
suicide ideation
High
Wilks  et al. [32] USA N = 59 Heavy episodic
alcohol intake
High emotional
dysregulation
>17 years Recruited through
online forums and
classiﬁeds
Delivered online
DBT
Weekly modules
with homework
over 8 weeks
Waiting list for
treatment
Beck Scale for
suicide ideation
Some concerns
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6862 references idenﬁed
4648 tles and abstracts 
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71 full-texts assessed for 
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publicaon type - 2
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Fig. 1. Prisma diagram.
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studies included.
Trials were diverse in terms of population, interventions, com-
parison groups and outcomes. Somewhat surprisingly, there was
no evidence of statistical heterogeneity, although this was likelynvestigated interventions for adults, except for one which investi-
ated cognitive behavioural therapy (CBT) in adolescents [29].
Five trials investigated psychosocial interventions: CBT [26,29],
ynamic deconstructive psychotherapy (DDT) [30,31], brief inter-
ention using Feedback about the adverse effects of excessive
lcohol consumption, an emphasis on Responsibility for change
ying with the individual, provision of Advice about reducing alco-
ol consumption, a Menu of options for further intervention if
his is required, an Empathic stance towards the patient, and the
nhancement of Self-efﬁcacy (FRAMES) [28], and online dialecti-
al behavioural therapy (DBT) [32]. The sixth trial, based in Iran,
ompared different high doses of buprenorphine (32 mg,  64 mg  or
6 mg)  speciﬁcally for men  with severe opioid use disorder [25].
reliminary evidence of effectiveness of low dose buprenorphine in
educing suicidal ideation amongst individuals without substance
isuse was cited as justiﬁcation for the trial [33,34].
In Ahmadi et al. [25], the comparison group received a lower
ose (32 mg)  of buprenorphine compared with the intervention
roup (96 mg). In two studies, the control group received optimised
ommunity care or enhanced treatment as usual. This involved
eferral to an alcohol rehabilitation centre and signposting to
uitable clinics/therapists in Gregory et al. [31], whilst in Esposito-
mythers et al. [29] treatment as usual was determined by external
roviders, but supplemented with a diagnostic evaluation that
as shared with community services, and medication manage-
ent by the trial psychiatrist. In Morley et al. [26], the comparison
roup received treatment as usual only, which could include phar-
acotherapy management and/or advice to seek support from
ommunity mental health services or the participants’ general
ractitioner. Finally, in the trial by Crawford et al. [28], the con-
rol group received a leaﬂet, and in Wilks et al. [32] participants
ere allocated to a waiting list for treatment.
Suicidal ideation was an outcome in four trials [25,26,29,32];
elf-reported self-harm [30,31] and emergency department re-
ttendance with self-harm [28] were outcomes in the remaining
rials. Follow-up time for measuring outcomes ranged from three
ays to 18 months.
Although all studies described the efﬁcacy of the interven-
ions, three were pilot feasibility trials [29,31,32], for which formal
ypothesis testing is not recommended [35]. The other three stud-
es acknowledged their sample size and/or power to be a limitation
25,26,28]. Furthermore, of the six trials included, three were
ssessed to be at high risk of bias [26,29,30,31], whilst there were
ome concerns regarding risk of bias for the remaining studies
Table 2).rehensive Psychiatry 96 (2020) 152135
3.3. Study ﬁndings
Results from four studies, which included suicidal ideation (as
a continuous variable) as the main outcome, are summarised in
Table 3. These studies investigated CBT, online-DBT and different
doses of buprenorphine. The SMD  was estimated to be negative,
favouring the intervention, in all studies. However, all estimates
were small (absolute SMD  < 0.2) and conﬁdence intervals were very
wide and inconclusive.
Results from three studies, which investigated a discrete pri-
mary outcome relating to suicide or self-harm, are summarised
in Table 4. Amongst the intervention groups at six months, there
was an estimated 43% reduction in the odds of re-attendance at
the emergency department with self-harm following a brief inter-
vention using the ‘FRAMES’ approach [28], and an estimated 52%
reduction in self-reported self-harm following DDT [31]. How-
ever, conﬁdence intervals around these results were very wide and
inconclusive. In Morley’s trial of an opportunistic CBT intervention
there was an estimated 42% increase in the presence of suicidal
ideation, but again the conﬁdence intervals were wide and incon-
clusive. Furthermore, this contrasted with the reduction in mean
difference of suicidal ideation scores noted in Table 3 [26].
The pooled estimate from a random effects meta-analysis of all
six RCTs was an SMD  of -0.20 (95% CI -0.39 to -0.00), indicating
weak evidence of a small effect of the intervention versus control
on suicide or self-harm. There was  no statistical evidence for het-
erogeneity (I-squared = 21.1%, p = 0.27), although this may  be due
to low power. When allowing for potential heterogeneity, a 95%
predictive interval for the true SMD  in a future study ranged from
-0.60 to 0.21. A sensitivity analysis with a ﬁxed effect model gave
a very similar pooled effect estimate but with a narrower conﬁ-
dence interval, indicating somewhat stronger evidence of a small
intervention effect (SMD = −0.23 95% CI-0.36 to −0.09). Results are
shown in Fig. 2. Visual inspection of the funnel plot did not highlight
any concerns about publication bias or other small study effects
(Supplementary File 4).
4. Discussion
We  found little evidence of an effective intervention to prevent
suicide or reduce self-harm among people with substance use dis-
orders. The pooled standardised mean difference with regards to
suicide or self-harm outcomes from a random effects meta-analysis
was small.
4.1. Strengths and limitations
To our knowledge this is the ﬁrst systematic review evaluating
interventions aimed at reducing self-harm or preventing suicide
amongst people with SUD. We  followed standardised procedures
for the assessment of bias and followed PRISMA guidelines in
reporting our ﬁndings. Nevertheless, the ﬁndings must be inter-
preted in light of the following limitations.
The review identiﬁed only a small number of trials, all with lim-
ited sample sizes. Crawford et al. (2014) estimated that a sample
size of 1400 would have been required to detect a 30% reduction
in self-harm repetition at six months with 80% power and a 5%
level of statistical signiﬁcance. The combined total of all partici-
pants across all six trials is approximately a third of the number
required to detect a potentially clinically important effect. Further-
more, we  had at least some concerns of bias with regards to all
P. Padmanathan, K. Hall, P. Moran et al. / Comprehensive Psychiatry 96 (2020) 152135 5
Table  2
Risk of bias summary (Green=low, yellow = some concerns, red=high).
Table 3
Summary of continuous primary outcome data (SD: standard deviation; SMD: standardised mean difference; CI: conﬁdence intervals).
Study Measure, timepoint Intervention, no.
participants with
outcome data
Intervention,
mean (SD)
Control, no.
participants with
outcome data
Control,
mean (SD)
Mean
difference
SMD  (95% CI)
Ahmadi et al. [25] BSSI score, day 3 14 0.00 (0.00) 16 0.63 (2.50) −0.63 −0.05 (-0.88, 0.77)
Esposito-Smythers et al. [29] SIQ-S, 6 months 17 28.65 (22.17) 17 38.24 (35.54) −9.59 −0.11 (-1.20, 0.99)
Morley  et al. [26] BSSI, 6 months 44 5.82 (5.58) 30 6.00 (6.61) −0.18 0.00 (-0.47, 0.46)
Wilks  et al. [32] BSSI, 4 months 24 5.45 (6.62) 26 9.59 (8.99) −4.14 −0.11 (-1.34, 1.12)
Table 4
Summary of discrete primary outcome data (SMD: standardised mean difference; CI: conﬁdence intervals).
Study Measure, timepoint Intervention, n (%
of those with
outcome data at
6 months)
Control, n (% of
those with
outcome data at
6  months)
Odds ratio
(95% CI)
SMD  (95% CI)
Crawford et al. [28] Re-attendance at emergency department with
self-harm, 6 months
7 (13) 11 (21) 0.57 (0.17-1.78) −0.31 (-0.48, -0.15)
Gregory et al. [31] Self-reported self-harm, 6 months 5 (45) 7 (64) 0.48 (0.06-3.49) −0.41 (-0.86, 0.04)
Morley  et al. [26] Presence of suicidal ideation (weekly), 6 months 6 (14) 3 (10) 1.42 (0.27-9.51) 0.19 (-0.14, 0.53)
 
NOTE:  Weights are from rando m eff ects analysis
.       (-0.60,  0.21 )with es timated  pred ictive interval
Overall  (I-squared = 21.1%, p = 0.274)
Ahmad i et  al. (2018 )
Grego ry et  al. (2008 )
Wil ks et  al. (2018 )
Study
Morley et  al. (2014 )
Crawford et  al. (2010 )
Esposito-Smythers et al. (2011)
30
22
50
size
74
103
Sample
34
-0.20 (-0.39, -0.00)
-0.05 (- 0.88,  0.77 )
-0.41 (- 0.86,  0.04 )
-0.11 (- 1.34,  1.12 )
ES (95% CI)
0.09 (- 0.20,  0.39 )
-0.31 (- 0.48, - 0.15 )
-0.11 (-1.20, 0.99)
100.00
5.02
14.47
2.33
Weight
26.65
48.62
%
2.92
   
0-1.34  1.34
Fig. 2. Forest plot of standardised mean differences for suicide or self-harm outcomes in each included study (Below 0 favours intervention; composite outcome included
for  Morley et al. [26].
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ue to small sample sizes. The wider 95% predictive interval pre-
ented may  be a better indication of the true amount of uncertainty
e have at present about the effectiveness of interventions. The
ooled result should therefore be interpreted with caution.
We considered the effect of treatment on two related but dis-
inct phenomena: self-harm and suicide-related outcomes. There
s, however, growing evidence of a distinction between non-
uicidal self-injury, suicidal ideation and suicide attempts [36].
onetheless intent can often ﬂuctuate and self-harm is a key risk
actor for suicide [37], and for these reasons we grouped both out-
omes together within one review.
.2. Findings in the context of the wider literature
A broad review of suicide prevention interventions highlighted
hat evidence is limited for interventions other than means restric-
ion, schools based awareness programmes and treatment of
sychiatric conditions [20]. Two systematic reviews of psychoso-
ial and pharmacological interventions for self-harm (irrespective
f intent), in adults speciﬁcally, were also limited in their ﬁndings
12,13]. The review of psychosocial interventions found low-
oderate quality evidence indicating a reduction in repetition
f self-harm following CBT-based interventions, and low quality
vidence regarding repetition of self-harm following DBT-based
nterventions. Evidence for a range of other approaches was incon-
lusive. The review of pharmacological interventions included only
even trials of 546 patients in total, and the quality of the evidence
as low or very low, prohibiting conclusions being drawn. Many
f the studies included in these reviews excluded people with a
istory of substance misuse. Furthermore, systematic reviews on
ual diagnosis have not explored suicide- or self-harm-related out-
omes [10,18].
In addition to the small number of identiﬁed trials measuring
uicide- or self-harm-related outcomes as the primary outcome,
everal trials were found which investigated these as secondary
r supplementary outcomes [38–46], or reported the suicide com-
onent of other scales separately, such as scales for depression
r aggression [47,48] (Supplementary File 5). In keeping with the
tudies reviewed here, these studies also found little evidence for
reatment effects but again were frequently subject to similar limi-
ations as the studies included in this review. An uncontrolled pilot
tudy of a suicide prevention module for patients attending group-
ased addiction treatment has had positive preliminary results
49]. A RCT of this module, with an estimated enrolment of 900
articipants, is currently in progress [50].
.3. Conclusion
Evidence is currently lacking regarding effective interventions
o prevent suicide and reduce self-harm amongst people with SUD.
CTs investigating suicidality and self-harm are vulnerable to type
I error, as well as bias resulting from inadequate blinding and the
se of self-reported measures. Given the importance of suicide and
elf-harm among people with SUD, there is a pressing need for ade-
uately powered and robustly conducted trials of new and existing
nterventions, examining suicide or self-harm-related primary out-
omes.
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